BOSTON and PLEASANTON, Calif. – The volume and diversity of data sources used in clinical trials are expected to increase significantly over the next three years, a report from the Tufts Center for the Study of Drug Development says.
The 2017 eClinical Landscape Study found that 97% of companies say they will increase use of at least one clinical data source to make faster, more accurate decisions during trials. However, 98% of respondents currently report challenges with their clinical data management systems, indicating that companies will need to be better prepared to collect and analyze the growing volume of real-world patient data available from a variety of sources.
“Clinical trial complexity is challenging scientific, operating and technology solution domains,” said Ken Getz, research associate professor and director at the Tufts Center for the Study of Drug Development, in a statement. “At the same time that clinical teams are managing traditional data from case report forms and local and central labs, they are being forced to step out of their comfort zone to manage, integrate and analyze data from more diverse and less compatible sources, including smart phone and wearable devices, real-world evidence and social media.”
Life sciences companies use an average of four data sources in clinical trials today. In three years, the number of data sources utilized is projected to increase to six, with 70% of companies planning to use a new data source that they are not leveraging today.
The survey also showed significant changes in the range of clinical information organizations plan to use in the next three years. A majority of companies plan to use mHealth and smart phone data (each increasing 47%) and eSource data (increasing 46%).
The 2017 eClinical Landscape Study was sponsored by Veeva Systems and reviewed the state of data management in life sciences with an in-depth look at the insights and opinions of clinical data management professionals at more than 250 companies.